Targeting VRK1 in glioblastoma cells, neuroblastomas, and pediatric gliomas, in which VRK2 has been eliminated or silenced by VRK2-promoter methylation cells [159,173], is a potential synthetic lethality strategy in these tumors. Here, VRK1 is linked to glioblastoma.